Tropisetron

Tropisetron, marketed under brand names such as Navoban, is a serotonin 5-HT3 receptor antagonist of the setron class, the same family of antiemetics that includes ondansetron and granisetron ^[1]. Chemically it is an indole derivative, an ester formed between indole-3-carboxylic acid and the tropane alcohol tropine, and it acts by blocking the 5-HT3 subtype of serotonin receptor in the gut and central nervous system ^[1].

Its principal established use is the prevention of chemotherapy-induced nausea and vomiting (CINV), a debilitating complication experienced by an estimated 70 to 80 percent of adults undergoing chemotherapy ^[1]. In this setting, 5-HT3 receptor antagonists such as tropisetron are combined with corticosteroids, and where needed with neurokinin-1 receptor antagonists, to control emesis during highly and moderately emetogenic chemotherapy ^[1]. Tropisetron is used in many countries in Europe, Asia, and elsewhere for this indication, though it has not been approved by the U.S. Food and Drug Administration.

What has made tropisetron especially interesting to researchers is a second pharmacological property: it acts as an agonist at the alpha7 nicotinic acetylcholine receptor (alpha7nAChR), a receptor central to the cholinergic anti-inflammatory pathway ^[2][4]. Through this receptor, tropisetron shows anti-inflammatory activity in a wide range of experimental models, including colitis, hemorrhagic cystitis, inflammatory skin responses, neuropathic pain, and neurodegeneration ^[3][4][5][6]. It has also been studied clinically as an analgesic, for instance in fibromyalgia. Tropisetron is available in oral and injectable forms and is generally used under medical supervision.

COMMON (label): at the 2 mg dose the most frequent reaction is headache. At 5 mg it is constipation, then less frequently dizziness, fatigue, somnolence and gastrointestinal effects including abdominal pain, diarrhoea and anorexia. In the pooled postoperative trials at 2 mg: bradycardia 10%, hypotension 8%, headache 4%, shivering 3%, hypertension 3%, skin reactions 1%, bronchospasm 1%. Placebo rates were similar for everything except headache (bradycardia 11%, hypotension 7% on placebo), so the label attributes most of these to the anaesthesia and surgery rather than the drug. Syncope and generalised urticaria occurred in under 1%.

SERIOUS BUT UNCOMMON: type 1 hypersensitivity reactions with flushing, generalised urticaria, chest discomfort, dyspnoea, acute bronchospasm and hypotension, as with the whole 5-HT3 class. Post-marketing reports, frequency not estimable: rash, erythema, anaphylactic reaction and shock (rare); collapse and cardiovascular arrest (very rare), some of which may be attributable to concurrent chemotherapy or the underlying malignancy.

CARDIAC: QTc prolongation described as not clinically significant has been observed after high intravenous doses up to 80 mg, and the label explicitly says a contribution from lower doses under general anaesthesia cannot be excluded. Caution in cardiac rhythm or conduction disturbances and in patients on antiarrhythmics or beta blockers, where experience with concurrent anaesthesia is limited, and with any other QT-prolonging drug. No dedicated thorough-QT study was located.

BLOOD PRESSURE: daily doses above 10 mg should be avoided in uncontrolled hypertension because they can raise blood pressure further. Overdose with very high repeated doses has produced VISUAL HALLUCINATIONS, and blood pressure rises in people with pre-existing hypertension; management is supportive.

CONTRAINDICATIONS: hypersensitivity to tropisetron or to other 5-HT3 receptor antagonists; pregnancy and lactation (this data sheet contraindicates both). Australian pregnancy category B3; no teratogenicity in rats, rabbits or monkeys, but increased post-implantation loss and delayed pup development at high doses, and increased post-natal loss in rats from 15 mg/kg/day. Excreted in rat milk; human milk transfer unknown. Not recommended in children. Carcinogenicity studies were negative except for benign hepatocellular neoplasia in male mice at 30 mg/kg/day and above; not mutagenic in standard assays.

INTERACTIONS: rifampicin, phenobarbital and other liver enzyme inducers lower tropisetron plasma levels and require a dose INCREASE in normal metabolisers but not in poor metabolisers. CYP inhibitors such as cimetidine have a negligible effect and need no adjustment. CYP2D6 genotype is the single largest determinant of exposure. Dizziness and fatigue may affect driving.

REGULATORY: prescription-only medicine. First marketed in Switzerland and Germany in 1992 as Navoban/Novaban, and subsequently approved by national procedures rather than a centralised EMA authorisation across Europe, Japan, South Korea, Taiwan, China, Australia, New Zealand, the Philippines and various Latin American markets. NEVER approved by the US FDA and not available in the United States; approval there was not pursued. The Novartis brand has since been discontinued in several markets (the Australian Navoban 5 mg capsule registration was cancelled by the sponsor in October 2014, and the UK injection was withdrawn), while generics and locally sponsored products such as Tropisetron-AFT injection in New Zealand remain on the market. ChEMBL's drug record shows max_phase 4, no black box warning and no withdrawn flag. On the WHO Model List of Essential Medicines (24th list, 2025) tropisetron appears only as a listed therapeutic alternative to ondansetron, not as an entry in its own right; the entry should not claim tropisetron is itself an essential medicine.

ANTI-DOPING: 5-HT3 receptor antagonist antiemetics do not fall within any prohibited class of the WADA Prohibited List and are not in the Monitoring Program, so tropisetron is not prohibited in or out of competition. This is inferred from the absence of the class from the List rather than from a WADA document naming tropisetron, which was not located; athletes should confirm the current status on Global DRO.

Tropisetron is metabolized primarily by CYP2D6, so its clearance varies with CYP2D6 phenotype; poor metabolizers show markedly higher plasma exposure while ultrarapid metabolizers show reduced exposure and potentially reduced antiemetic effect. Strong CYP inducers such as rifampicin lower tropisetron plasma concentrations by accelerating its metabolism. As a 5-HT3 antagonist that can prolong the QT interval, tropisetron carries an additive arrhythmia risk when combined with other QT-prolonging drugs (for example certain antiarrhythmics, antipsychotics, and other setrons) and with agents that cause hypokalemia. Coadministration with other serotonergic drugs has a theoretical serotonin-related concern but this is not well documented for tropisetron specifically. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Tropisetron was developed by the Swiss pharmaceutical company Sandoz (a predecessor of Novartis) as part of the first generation of selective 5-HT3 receptor antagonists that emerged in the late 1980s, when researchers recognized that serotonin released from the gut during chemotherapy was a principal trigger of nausea and vomiting.

It reached the market around 1992 under the brand name Navoban and became widely used across Europe, Asia, and other regions to prevent chemotherapy-induced and postoperative emesis, though it was never submitted for approval in the United States. For most of its clinical life it was regarded simply as a dependable antiemetic with a long safety record.

Interest broadened considerably once pharmacologists discovered that tropisetron is also a potent agonist at the alpha7 nicotinic acetylcholine receptor, a target implicated in the cholinergic anti-inflammatory pathway and in cognition. This second mechanism, absent from its original design brief, has since driven a wave of preclinical research into repurposing the molecule for pain, inflammatory, and neurodegenerative conditions.

Tropisetron enjoys a strong reputation as an effective and well-tolerated antiemetic, backed by decades of clinical use in oncology and surgery. What distinguishes it within the setron class is its dual pharmacology; because it engages the alpha7 nicotinic receptor in addition to blocking 5-HT3, it carries an anti-inflammatory and pain-modulating dimension that most of its peers lack.

Preclinical studies have reported neuroprotective, analgesic, and immune-calming effects across models of colitis, neuropathic pain, and Huntington's disease, generating genuine scientific enthusiasm for repurposing an already familiar drug.

It is worth emphasizing that these broader benefits remain largely at the experimental stage and have not been established for these new uses in humans. Still, the combination of a proven clinical foundation and a distinctive second mechanism makes tropisetron an unusually compelling molecule.